Ranbaxy Labs has recalled over 64,000 bottles of Atorvastatin calcium tablets, a generic version of the cholesterol-lowering Lipitor, after complaints of wrong dosage. Ranbaxy, which has been facing regulatory action by the US Food and Drug Administration (USFDA) in the past, had to recall the drug after a complaint by a pharmacist, who found a 20 mg tablet in a bottle of Atorvastatin 10 mg tablets.
The company, now owned by Daiichi Sankyo of Japan, has withdrawn the lots as a precaution, keeping the safety of patients in mind. Earlier in January, the USFDA had prohibited Ranbaxy from producing and distributing drugs for the US market produced at its Toansa planty in Punjab.This plant catered to over 70% of Ranbaxy’s requirements for raw material for formulations. Toansa is the fourth Ranbaxy plant banned by the US regulator. In September, the USFDA had imposed an import alert on Ranbaxy’s Mohali plant due to violation of good manufacturing practices. Besides, Ranbaxy’s plants at Paonta Sahib and Dewas have been facing a US import alert since 2008.